Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

SAN FRANCISCO -- In order to maximize weight loss, a GLP-1 receptor agonist may be needed both before and after bariatric ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

New study published by Truveta and Harvard Medical School A groundbreaking study published today in Pediatrics Open Science ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...